Japan bladder cancer market was valued at $268.7 million in 2025 and is projected to reach $498.1 million by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035). Japan continues to face a significant clinical burden from bladder cancer, with approximately 25,000 new cases diagnosed annually and nearly 9,500 fatalities reported in 2023. High-risk BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) represents a major unmet medical need, as patients who do not respond to Bacillus Calmette-Guérin therapy are frequently considered for radical cystectomy. However, in April 2025, phase 3 findings for nadofaragene firadenovec-vncg (Adstiladrin) reported a 75% complete response rate at three months among Japanese patients with carcinoma in situ with or without papillary tumors (±Ta/T1), based on trial NCT05704244. The therapy demonstrated a manageable safety profile, with most treatment-related adverse events categorized as grade 1 or 2 and no grade 3 or higher events observed. These data were presented at the 112th Annual Meeting of the Japanese Urological Association, underscoring increasing clinical and research attention toward gene-based intravesical therapies in Japan.
Browse the full report description of “Japan Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (Ivp), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/japan-bladder-cancer-market
Approved in the US in December 2022, nadofaragene firadenovec represents a novel intravesical gene therapy designed to provide bladder-preserving benefit in patients with limited options. Its ongoing phase 3 evaluation in Japan, with study completion anticipated in 2029, reflects broader efforts to expand advanced therapeutic modalities within the domestic oncology market. Compared with historical response rates observed in earlier global trials, the Japanese data suggest encouraging efficacy trends that may influence future regulatory and reimbursement considerations. As innovation shifts toward precision and gene-based interventions, such advancements are expected to create measurable growth opportunities in Japan’s bladder cancer market, particularly in segments addressing BCG-unresponsive disease.
Key Player Developments in Japan’s Bladder Cancer Market
Major market players operating in the bladder cancer market include Merck Sharp & Dohme K.K. (MSD K.K.), Bristol-Myers Squibb K.K., Astellas Pharma Inc., Pfizer Japan Inc., and Janssen Pharmaceutical K.K. These companies are actively focused on expanding immunotherapy indications, advancing combination treatment strategies, and strengthening clinical trial pipelines to address high-risk and advanced-stage bladder cancer.
Market Coverage
Key questions addressed by the report.
Japan Bladder Cancer Market Report Segment
Cancer Type
Diagnosis Method
By Therapy
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-bladder-cancer-market